5 Best Genomics Stocks to Buy According to Analysts

4. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Analysts’ Upside Potential: 63.79%

On May 26, Pacific Biosciences of California, Inc. (NASDAQ:PACB) began global shipments of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio platform. The firm lowered the per-genome list price to $345 and authorized sub-$300 sequencing at scale. The company said the new chemistry cuts costs by about 30%. It also improved accuracy and yield through updates to its artificial intelligence-powered DeepConsensus algorithm developed with Google.

The company said beta testing across more than 1,400 runs showed higher yield and lower failure rates. Associate Professor and Senior Bioinformatician at Uppsala University, Adam Ameur, stated the system delivered “consistently strong run performance” with lower pricing and simplified workflows. CEO Christian Henry said AI advances, “improving data quality, speed, and usability,” are expanding what researchers can extract from each run.

Product Lead for Genomics at Google Research, Andrew Carroll, added that DeepConsensus upgrades introduce more data quality, while PacBio said expanded methylation detection and reusable consumables increase output and reduce costs.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a firm that develops, manufactures, and markets advanced sequencing solutions for genetic analysis. It operates through America, Europe, the Middle East, and Africa, and Asia Pacific segments.